News and media

We are consulting on the proposed remaking of the Narcotic Drugs Regulation 2016 and the Narcotic Drugs (Licence Charges) Regulation 2016 (legislative instruments), which are scheduled to sunset on 1 April 2027.

MCEWG Meeting 7 highlights medicinal cannabis policy developments, TGA consultation findings, research updates and the group's renewed tenure.

Infringement notice issued to Hale Farm Pty Ltd totalling $19,800 for an alleged breach of its medicinal cannabis licence.

The ODC has given an infringement notice totalling $19,800 to Cannatrek Technologies Pty Ltd for alleged breaches of its medicinal cannabis licence.

The ODC has given an infringement notice totalling $19,800 to Cannoperations Pty Ltd for an alleged breach of its medicinal cannabis licence.

Infringement notices totalling $39,600 issued to MedTEC Services Pty Ltd for alleged breaches of its medicinal cannabis licence.

MCEWG Meeting 6 highlights medicinal cannabis regulation, TGA safety consultation, high-THC policy approaches and challenges in pharmacovigilance.

The 2024 data on cannabis-related activities regulated by the Office of Drug Control is now available.

Infringement notices totalling $39,600 issued to Tasmanian Botanics Pty Ltd for alleged breaches of its medicinal cannabis licence.

Infringement notice of $19,800 issued to Cannatrek Technologies Pty Ltd for alleged breaches of its medicinal cannabis licence.

MCEWG Meeting 5 discusses medicinal cannabis regulatory requirements, clinical guidance, prescribing trends, dispensing issues and educational resources.

Subscribe to our newsletter for updates on key developments, industry topics and important issues related to our work and engagement.

MCEWG Meeting 4 discusses Queensland medicinal cannabis initiatives, pharmacy compounding guidance, TGO 93 standards and product quality issues.

From 1 March 2025, certain Schedule 4 substances will require a licence and permit for import or export under the Customs (Prohibited Imports) Regulations.

MCEWG Meeting 3 discusses updates to medicinal cannabis clinical guidance, research on high-THC products and safe prescribing through AMT coding.

The HBS Portal is open for new medicinal cannabis and narcotic drug manufacture licence applications to the Office of Drug Control.

MCEWG Meeting 2 highlights medicinal cannabis vape regulation, prescription monitoring challenges, patient safety and high-potency THC research.

The 2023 data on cannabis-related activities regulated by the Office of Drug Control is now available.

MCEWG Meeting 1 highlights medicinal cannabis access, product quality standards, prescribing trends, regulation and the group's forward workplan.

Transition to an online system for submitting new licence applications from mid‑2024, including changes to how applications are prepared and submitted.

This year we will be establishing an online portal, making it easier and more convenient for you to do business with us.

Find out about new substances requiring a licence and permit for import and/or export issued by us, the Office of Drug Control (ODC), From 21 February 2024.

New import controls have been introduced for vaping goods under the Customs (Prohibited Imports) Regulations 1956.

Kava pilot ends on 31 December 2023, with a decision on future imports pending; importers can continue applying for permissions in the meantime.

From 13 December 2023 there are new substances requiring a licence and permit for import and export.